<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02952924</url>
  </required_header>
  <id_info>
    <org_study_id>YP39364</org_study_id>
    <nct_id>NCT02952924</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants</brief_title>
  <official_title>A Safety, Tolerability, Pharmacokinetics and Efficacy Study of ro7049389 in: (1) Single- (With or Without Food) and Multiple- (With Midazolam) Ascending Doses in Healthy Volunteers; (2) Patients Chronically Infected With Hepatitis b Virus (3) Patients With Chronic Hepatitis B.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study is a multicenter, three-part study. Parts 1 and 2 are randomized, investigator-&#xD;
      and participant-blinded, placebo-control, single-ascending dose (SAD) and multiple-ascending&#xD;
      dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK) and&#xD;
      pharmacodynamics (PD) of RO7049389 following oral administration in healthy volunteers and&#xD;
      chronic HBV infected participants. Part 3 is a non-randomized, non-controlled, open-label&#xD;
      part to assess the efficacy and safety of RO7049389 when administered in combination with&#xD;
      standard-of-care therapies for up to 48 weeks in nucleos(t)ide (NUC)-suppressed and&#xD;
      treatment-naive chronic hepatitis B (CHB) participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 14, 2016</start_date>
  <completion_date type="Anticipated">August 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Percentage of Participants With Adverse Events</measure>
    <time_frame>From randomization up to Day 44</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Percentage of Participants With Adverse Events</measure>
    <time_frame>From randomization up to Day 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: HBV DNA Level</measure>
    <time_frame>Baseline; Days 8, 15, 22, 28, 35, 56, 84, and 112</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1c- MAD Cohort: Area Under the Plasma Concentration Versus Time Curve for a Dosing Interval (AUC0-tau) of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hrs post Day 1 morning dose; pre-dose (0 hr) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post Day 14 morning dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1c- MAD Cohort: Plasma Trough Concentration (Ctrough) of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr before morning dose) on Days 2, 3, 4, 5, 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1c- MAD Cohort: Apparent Terminal t1/2 of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hrs post Day 1 morning dose; pre-dose (0 hr) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post Day 14 morning dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1c- MAD Cohort: Accumulation Index of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hrs post Day 1 morning dose; pre-dose (0 hr) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post Day 14 morning dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1c- MAD Cohort: Ae of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr), 0-4, 4-8, 8-12, 12-24 hours post morning dose on Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1c- MAD Cohort: CLR of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr), 0-4, 4-8, 8-12, 12-24 hours post morning dose on Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1a- SAD Cohort: Maximum Observed Plasma Concentration (Cmax) of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hour [hr]) on Day 1; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hrs post Day 1 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1a- SAD Cohort: Time to Reach Cmax (Tmax) of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr) on Day 1; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hrs post Day 1 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1a- SAD Cohort: Area Under the Plasma Concentration Versus Time Curve up to the Last Measurable Concentration (AUC0-last) of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr) on Day 1; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hrs post Day 1 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1a- SAD Cohort: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr) on Day 1; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hrs post Day 1 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1a- SAD Cohort: Apparent Terminal Half-life (t1/2) of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr) on Day 1; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hrs post Day 1 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1a- SAD Cohort: Apparent Oral Clearance (CL/F) of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr) on Day 1; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hrs post Day 1 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1a-SAD Cohort- Cumulative Amount Excreted Unchanged in Urine (Ae) of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr) on Day 1; 0-4, 4-8, 8-12, 12-24, 24-48 hours post Day 1 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1a- SAD Cohort: Renal Clearance (CLR) of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr) on Day 1; 0-4, 4-8, 8-12, 12-24, 24-48 hours post Day 1 dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1c- MAD Cohort: Cmax of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hrs post Day 1 morning dose; pre-dose (0 hr) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post Day 14 morning dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1c- MAD Cohort: Tmax of RO7049389 and Metabolites</measure>
    <time_frame>Pre-dose (0 hr) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hrs post Day 1 morning dose; pre-dose (0 hr) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hrs post Day 14 morning dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3 HBV DNA Level</measure>
    <time_frame>Every 2-4 weeks from Baseline through Week 72</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: HBsAg Level</measure>
    <time_frame>Every 2-4 weeks from baseline through week 72</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1b- Food-Effect SAD Cohort: Cmax of RO7049389</measure>
    <time_frame>Pre-dose (0 hr) on Day 16; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hrs post Day 16 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b- Food-Effect SAD Cohort: Tmax of RO7049389</measure>
    <time_frame>Pre-dose (0 hr) on Day 16; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hrs post Day 16 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b- Food-Effect SAD Cohort: AUC0-last of RO7049389</measure>
    <time_frame>Pre-dose (0 hr) on Day 16; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hrs post Day 16 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b- Food-Effect SAD Cohort: AUC0-inf of RO7049389</measure>
    <time_frame>Pre-dose (0 hr) on Day 16; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hrs post Day 16 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b- Food-Effect SAD Cohort: Apparent Terminal t1/2 of RO7049389</measure>
    <time_frame>Pre-dose (0 hr) on Day 16; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hrs post Day 16 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b- Food-Effect SAD Cohort: Apparent CL/F of RO7049389</measure>
    <time_frame>Pre-dose (0 hr) on Day 16; 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 and 96 hrs post Day 16 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c- MAD Cohort: Cmax of Midazolam</measure>
    <time_frame>Pre-dose (0 hr), 0.25, 0.5,1, 2, 4, 6, 8, 10, and 12 hrs post-midazolam dose on Day -1; pre-RO7049389 dose (0 hr) on Day 1; pre-dose (0 hr), 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hrs post-midazolam dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c- MAD Cohort: Tmax of Midazolam</measure>
    <time_frame>Pre-dose (0 hr), 0.25, 0.5,1, 2, 4, 6, 8, 10, and 12 hrs post-midazolam dose on Day -1; pre-RO7049389 dose (0 hr) on Day 1; pre-dose (0 hr), 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hrs post-midazolam dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c- MAD Cohort: AUC0-last of Midazolam</measure>
    <time_frame>Pre-dose (0 hr), 0.25, 0.5,1, 2, 4, 6, 8, 10, and 12 hrs post-midazolam dose on Day -1; pre-RO7049389 dose (0 hr) on Day 1; pre-dose (0 hr), 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hrs post-midazolam dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c- MAD Cohort: AUC0-inf of Midazolam</measure>
    <time_frame>Pre-dose (0 hr), 0.25, 0.5,1, 2, 4, 6, 8, 10, and 12 hrs post-midazolam dose on Day -1; pre-RO7049389 dose (0 hr) on Day 1; pre-dose (0 hr), 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hrs post-midazolam dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c- MAD Cohort: Area Under the Plasma Concentration Versus Time Curve up to 6 h Post-dose (AUC0-6h) of Midazolam</measure>
    <time_frame>Pre-dose (0 hr), 0.25, 0.5,1, 2, 4, 6, 8, 10, and 12 hrs post-midazolam dose on Day -1; pre-RO7049389 dose (0 hr) on Day 1; pre-dose (0 hr), 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hrs post-midazolam dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c- MAD Cohort: Apparent Terminal t1/2 of Midazolam</measure>
    <time_frame>Pre-dose (0 hr), 0.25, 0.5,1, 2, 4, 6, 8, 10, and 12 hrs post-midazolam dose on Day -1; pre-RO7049389 dose (0 hr) on Day 1; pre-dose (0 hr), 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hrs post-midazolam dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1c- MAD Cohort: CL/F of Midazolam</measure>
    <time_frame>Pre-dose (0 hr), 0.25, 0.5,1, 2, 4, 6, 8, 10, and 12 hrs post-midazolam dose on Day -1; pre-RO7049389 dose (0 hr) on Day 1; pre-dose (0 hr), 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hrs post-midazolam dose on Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of RO7049389</measure>
    <time_frame>Pre-dose (0 hr) and 1, 2, 3, 4, 6, and 8 hrs post Day 1 morning dose; pre-dose (0 hr) and 1, 2, 3, 4, 6, 8, and 24 hrs post Day 28 morning dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Tmax of RO7049389</measure>
    <time_frame>Pre-dose (0 hr) and 1, 2, 3, 4, 6, and 8 hrs post Day 1 morning dose; pre-dose (0 hr) and 1, 2, 3, 4, 6, 8, and 24 hrs post Day 28 morning dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC0-tau of RO7049389</measure>
    <time_frame>Pre-dose (0 hr) and 1, 2, 3, 4, 6, and 8 hrs post Day 1 morning dose; pre-dose (0 hr) and 1, 2, 3, 4, 6, 8, and 24 hrs post Day 28 morning dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Ctrough of RO7049389</measure>
    <time_frame>Pre-morning dose (0 hr) on Days 2, 3, 4, 8, 15, 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Apparent t1/2 of RO7049389</measure>
    <time_frame>Pre-dose (0 hr) and 1, 2, 3, 4, 6, and 8 hrs post Day 1 morning dose; pre-dose (0 hr) and 1, 2, 3, 4, 6, 8, and 24 hrs post Day 28 morning dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Accumulation Index of RO7049389</measure>
    <time_frame>Pre-dose (0 hr) and 1, 2, 3, 4, 6, and 8 hrs post Day 1 morning dose; pre-dose (0 hr) and 1, 2, 3, 4, 6, 8, and 24 hrs post Day 28 morning dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Anti-HBe Antibodies</measure>
    <time_frame>Baseline; Days 8,15,22,28,35,56,84, and 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Cmax of RO7049389 and its Metabolites</measure>
    <time_frame>Pre-dose and 1,2,3,4,6, and 8 hours post-dose (Day 1, Week 4 (Cohort B only) and Week 24); pre-dose and 1,2,3,4,6,8, and 24 hours after the last dose (Week 48)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Tmax of RO7049389 and its metabolites</measure>
    <time_frame>Pre-dose and 1,2,3,4,6, and 8 hours post-dose (Day 1, Week 4 (Cohort B only) and Week 24); pre-dose and 1,2,3,4,6,8, and 24 hours after the last dose (Week 48)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: AUC0-tau of RO7049389 and its metabolites</measure>
    <time_frame>Pre-dose and 1,2,3,4,6, and 8 hours post-dose (Day 1, Week 4 (Cohort B only) and Week 24); pre-dose and 1,2,3,4,6,8, and 24 hours after the last dose (Week 48)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Ctrough of RO7049389 and its metabolites</measure>
    <time_frame>Pre-dose Days 14 and 28; thereafter predose every 28 days up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: T1/2 of RO7049389 and its metabolites</measure>
    <time_frame>Pre-dose and 1,2,3,4,6, and 8 hours post-dose (Day 1, Week 4 (Cohort B only) and Week 24); pre-dose and 1,2,3,4,6,8, and 24 hours after the last dose (Week 48)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Accumulation Index of RO7049389 and its Metabolites</measure>
    <time_frame>Pre-dose and 1,2,3,4,6, and 8 hours post-dose (Day 1, Week 4 (Cohort B only) and Week 24); pre-dose and 1,2,3,4,6,8, and 24 hours after the last dose (Week 48)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Ctrough of Nucleos(t)ide Analogs (NUCs)</measure>
    <time_frame>Pre-dose Days 14 (Cohort A and C only) and 28; thereafter predose every 28 days up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Hepatitis B e-Antigen (HBeAg) Levels</measure>
    <time_frame>Every 2-4 weeks from Baseline through Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Anti-HBs Antibodies</measure>
    <time_frame>Every 2-4 weeks from Baseline through Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Anti-HBe Antibodies</measure>
    <time_frame>Every 2-4 weeks from Baseline through Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Anti-HBc antibodies</measure>
    <time_frame>Every 2-4 weeks from Baseline through Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: HBV RNA Level</measure>
    <time_frame>Every 2-4 weeks from Baseline through Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: HBV Core-Related Antigen Levels (HBcrAg)</measure>
    <time_frame>Every 2-4 weeks from baseline through week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Viral Resistance Monitoring</measure>
    <time_frame>Every 2-4 weeks from baseline through week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3 Percentage of Participants With Adverse Events</measure>
    <time_frame>From randomization up to 72 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Parts 1a and 1b: SAD in Healthy Volunteers (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Part 1a, participants will receive a single oral dose of placebo matching to RO7049389 film coated tablet on Day 1. In Part 1b, minimum 8 participants from Part 1a will be selected and 2 of whom will receive another single dose of placebo matching to RO7049389 on Day 16 after eating the standard United States - Food and Drug Administration (US FDA)-recommended high-fat and high-calorie breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parts 1a and 1b: SAD in Healthy Volunteers (RO7049389)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1a, participants will receive a single oral dose of RO7049389 film coated tablet on Day 1 in dose-escalation cohorts with a starting dose of 150 milligrams (mg). The doses for subsequent cohorts will be defined by an adaptive approach based on the safety and PK data in previously-dosed healthy volunteers. In Part 1b, minimum 8 participants from Part 1a will be selected and 6 of whom will receive another single dose of RO7049389 on Day 16 after eating the standard US FDA-recommended high-fat and high-calorie breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1c: MAD in Healthy Volunteers (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 13 (either once a day [QD] or twice a day [BID]) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 micrograms [mcg]) on Day -1 and Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1c: MAD in Healthy Volunteers (RO7049389)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7049389 film coated tablet from Days 1 to 13 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 mcg) on Day -1 and Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: POM in Chronic HBV Participants (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 27 (either QD or BID) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: POM in Chronic HBV Participants (RO7049389)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7049389 film coated tablet from Days 1 to 27 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: POM in NUC-Suppressed CHB Participants (Cohort A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7049389 on top of a NUC for 48 weeks at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: POM in Treatment-Naive CHB Participants (Cohort B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7049389 for 4 weeks, followed by RO7049389 with an added NUC for 44 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: POM in Treatment-Naive CHB Participants (Cohort C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RO7049389 + NUC + Pegylated-Interferon (Peg-IFN) for 48 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC and Peg-IFN therapy will be administered per local label or guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo</description>
    <arm_group_label>Part 1c: MAD in Healthy Volunteers (Placebo)</arm_group_label>
    <arm_group_label>Part 1c: MAD in Healthy Volunteers (RO7049389)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to RO7049389 will be administered as per schedule described in individual arm.</description>
    <arm_group_label>Part 1c: MAD in Healthy Volunteers (Placebo)</arm_group_label>
    <arm_group_label>Part 2: POM in Chronic HBV Participants (Placebo)</arm_group_label>
    <arm_group_label>Parts 1a and 1b: SAD in Healthy Volunteers (Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7049389</intervention_name>
    <description>RO7049389 will be administered as per schedule described in individual arm.</description>
    <arm_group_label>Part 1c: MAD in Healthy Volunteers (RO7049389)</arm_group_label>
    <arm_group_label>Part 2: POM in Chronic HBV Participants (RO7049389)</arm_group_label>
    <arm_group_label>Part 3: POM in NUC-Suppressed CHB Participants (Cohort A)</arm_group_label>
    <arm_group_label>Part 3: POM in Treatment-Naive CHB Participants (Cohort B)</arm_group_label>
    <arm_group_label>Part 3: POM in Treatment-Naive CHB Participants (Cohort C)</arm_group_label>
    <arm_group_label>Parts 1a and 1b: SAD in Healthy Volunteers (RO7049389)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part 1- Healthy Volunteers only:&#xD;
&#xD;
          -  Absence of evidence of any active or chronic disease following a detailed medical and&#xD;
             surgical history, a complete physical examination including vital signs, 12-lead&#xD;
             Electrocardiogram (ECG), hematology, blood chemistry, serology and urinalysis&#xD;
&#xD;
          -  A Body Mass Index (BMI) between 18 to 30 kilograms per square meter (kg/m^2) inclusive&#xD;
&#xD;
          -  Female participants must be either surgically sterile or post-menopausal for at least&#xD;
             one year&#xD;
&#xD;
          -  For men: agreement to remain abstinent or use contraceptive measures, and agreement to&#xD;
             refrain from donating sperm&#xD;
&#xD;
        Part 2- Chronic HBV-infected participants only:&#xD;
&#xD;
          -  A BMI between 18 to 30 kg/m^2 inclusive&#xD;
&#xD;
          -  Chronic Hepatitis B infection, defined as positive test for Hepatitis B surface&#xD;
             antigen (HBsAg) for more than 6 months prior to randomization&#xD;
&#xD;
          -  HBV DNA at screening greater than or equal to (&gt;/=) 2 × 10^4 international units per&#xD;
             milliliter (IU/mL) for Hepatitis B e antigen (HBeAg) positive participants, or &gt;/=2 ×&#xD;
             10^3 IU/mL for HBeAg-negative participants&#xD;
&#xD;
          -  Liver biopsy, fibroscan or equivalent test obtained within the past 6 months&#xD;
             demonstrating liver disease consistent with chronic HBV infection with absence of&#xD;
             extensive bridging fibrosis and absence of cirrhosis&#xD;
&#xD;
          -  For men: agreement to remain abstinent or use contraceptive measures, and agreement to&#xD;
             refrain from donating sperm&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent or use non-hormonal&#xD;
             contraceptive methods that result in a failure rate of less than (&lt;)1 percent (%) per&#xD;
             year during the treatment period and for at least 3 months after the last dose of&#xD;
             study drug&#xD;
&#xD;
        Part 3- Chronic HBV Participants Only:&#xD;
&#xD;
          -  A BMI between 18 to 32 kg/m^2 inclusive&#xD;
&#xD;
          -  Chronic hepatitis B infection, defined as positive test for HBsAg or HBV DNA, or&#xD;
             positive HBeAg, for more than 6 months prior to screening&#xD;
&#xD;
          -  For Cohorts only enrolling NUC-suppressed CHB participants (e.g. POM Cohort A),&#xD;
             participants must have been treated with a single NUC (entecavir, tenofovir&#xD;
             alafenamide, or tenofovir disoproxil fumarate) for at least 12 months. Participants&#xD;
             must be on the same NUC therapy for at least 3 months prior to screening&#xD;
&#xD;
          -  For Cohorts only enrolling anti-HBV treatment-naive and immune-active participants&#xD;
             (e.g. POM Cohort B and Cohort C), previous anti-HBV treatments &lt;30 days in total, and&#xD;
             did not receive any anti-HBV treatments within 3 months prior to the first study dose&#xD;
&#xD;
          -  Liver biopsy, fibroscan, or equivalent test obtained within the past 6 months&#xD;
             demonstrating liver disease consistent with chronic HBV infection with absence of&#xD;
             extensive bridging fibrosis and absence of cirrhosis&#xD;
&#xD;
          -  For men: agreement to remain abstinent or use contraceptive measures, and agree to&#xD;
             refrain from donating sperm&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent or to use two&#xD;
             approved contraceptive methods during the study and for at least 6 months after the&#xD;
             last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Part 1- Healthy Volunteers only:&#xD;
&#xD;
          -  History or symptoms of any clinically significant gastrointestinal, renal, hepatic,&#xD;
             broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological,&#xD;
             hematological or allergic disease, metabolic disorder, cancer or cirrhosis&#xD;
&#xD;
          -  History of Gilbert's syndrome&#xD;
&#xD;
          -  Participants who have had significant acute infection, e.g., influenza, local&#xD;
             infection, acute gastrointestinal symptoms or any other clinically significant illness&#xD;
             within two weeks of dose administration&#xD;
&#xD;
          -  Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any&#xD;
             drug, or multiple drug allergies&#xD;
&#xD;
          -  Any clinically significant concomitant diseases or condition that could interfere&#xD;
             with, or treatment of which might interfere with, the conduct of the study, or that&#xD;
             would, in the opinion of the Investigator, pose an unacceptable risk to the&#xD;
             participant in this study&#xD;
&#xD;
          -  Positive test at screening of any of the following: Hepatitis A (HAV IgM Ab),&#xD;
             Hepatitis B (HBsAg), Hepatitis C (HCV RNA or HCV Ab) or human immunodeficiency virus&#xD;
             (HIV Ab)&#xD;
&#xD;
          -  Acute narrow-angle glaucoma (for MAD-midazolam cohorts)&#xD;
&#xD;
        Part 2- Chronic HBV-infected participants only:&#xD;
&#xD;
          -  History or other evidence of bleeding from esophageal varices&#xD;
&#xD;
          -  Evidence of liver cirrhosis or decompensated liver disease such as ascites, esophageal&#xD;
             or gastric varices, splenomegaly, nodular liver, jaundice, hepatic encephalopathy&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HBV infection (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver&#xD;
             disease, toxin exposure, thalassemia, nonalcoholic steatohepatitis, etc.)&#xD;
&#xD;
          -  Documented history or other evidence of metabolic liver disease within one year of&#xD;
             randomization&#xD;
&#xD;
          -  Positive test for hepatitis A (IgM anti-HAV), hepatitis C, hepatitis D, or human&#xD;
             immunodeficiency virus&#xD;
&#xD;
          -  History of or suspicion of hepatocellular carcinoma or alphafetoprotein &gt;/= Upper&#xD;
             limit of normal (ULN) at screening&#xD;
&#xD;
          -  History of clinically significant gastrointestinal, cardiovascular, endocrine, renal,&#xD;
             ocular, pulmonary, psychiatric or neurological disease&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  Previous or concurrent HBV treatments in the past 6 months&#xD;
&#xD;
          -  Significant acute infection (e.g., influenza, local infection) or any other clinically&#xD;
             significant illness within 2 weeks of randomization&#xD;
&#xD;
        Part 3- Chronic Hepatitis B Participants Only:&#xD;
&#xD;
          -  History or other evidence of bleeding from esophageal varices&#xD;
&#xD;
          -  Evidence of liver cirrhosis or decompensated liver disease such as ascites, esophageal&#xD;
             or gastric varices, splenomegaly, nodular liver, jaundice, or hepatic encephalopathy&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HBV infection (e.g. hemochromatosis, autoimmune hepatitis, alcoholic liver&#xD;
             disease, toxin exposure, thalassemia, nonalcoholic statohepatitis, etc.)&#xD;
&#xD;
          -  History of thyroid disease poorly controlled on prescribed medications or clinically&#xD;
             relevant abnormal thyroid function tests&#xD;
&#xD;
          -  Documented history or other evidence of metabolic liver disease within one year of&#xD;
             screening&#xD;
&#xD;
          -  Positive test for hepatitis A (IgM anti-HAV), hepatitis C, hepatitis D, HEV, or HIV&#xD;
&#xD;
          -  Diagnosed or suspected hepatocellular carcinoma&#xD;
&#xD;
          -  History of clinically significant gastrointestinal, cardiovascular, endocrine, renal,&#xD;
             ocular, pulmonary, psychiatric, or neurological disease&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  Significant acute infection (e.g. influenza, local infection) or any other clinically&#xD;
             significant illness within 2 weeks of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem City Clinic Tokuda Hospital Ead</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai City</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong; Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited</name>
      <address>
        <city>Grafton</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Health System</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Kaohsiung Branch</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans Gen Hosp</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70457</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou Branch</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Hong Kong</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

